Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shom Goel

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Cancer Cell|October 11, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionRei Kudo, Anton Safonov, Catherine Jones, et al.
Immunity|May 22, 2024
The CD8<sup>+</sup> T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defectsWillem Van Der Byl, Simone Nüssing, Timothy J Peters, et al.
Nature Cancer|May 17, 2021
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C Watt, Paloma Cejas, Molly J DeCristo, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Future Oncology (London, England)|July 29, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancerKamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Cancers|September 10, 2021
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx<sup>®</sup> Digital Spatial ProfilerHelga Bergholtz, Jodi M Carter, Alessandra Cesano, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cancer Cell|October 11, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionRei Kudo, Anton Safonov, Catherine Jones, et al.
Immunity|May 22, 2024
The CD8<sup>+</sup> T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defectsWillem Van Der Byl, Simone Nüssing, Timothy J Peters, et al.
Nature Cancer|May 17, 2021
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C Watt, Paloma Cejas, Molly J DeCristo, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Future Oncology (London, England)|July 29, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancerKamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Cancers|September 10, 2021
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx<sup>®</sup> Digital Spatial ProfilerHelga Bergholtz, Jodi M Carter, Alessandra Cesano, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Pageof 7